EA
VNDA icon

Emerald Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

Emerald Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-258,497
Closed -$4.24M – 317
2019
Q4 		$4.24M Buy
+258,497
New +$3.91M 0.18% 117

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Emerald Advisers's VNDA Position: Q1 2020 in Review

Emerald Advisers sold out of Vanda Pharmaceuticals (VNDA) in Q1 2020, closing a stake of 258,497 shares — an estimated $4.24M sold.

Emerald Advisers first reported a position in VNDA in Q4 2019 and held it in 1 quarter. The position peaked at $4.24M in Q4 2019. 159 funds tracked by Wall St. Rank hold VNDA as of Q1 2020.

  • Emerald Advisers reported no remaining Vanda Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Emerald Advisers sold 258,497 Vanda Pharmaceuticals shares in Q1 2020, an estimated $4.24M.
  • Emerald Advisers first reported a position in Vanda Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Emerald Advisers's Vanda Pharmaceuticals position peaked at $4.24M in Q4 2019.
  • 159 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2020.

Based on Emerald Advisers's 13F filing for Q1 2020, filed 30 Apr 2020.